Your browser is no longer supported. Please, upgrade your browser.
Settings
OMER Omeros Corporation daily Stock Chart
OMER [NASD]
Omeros Corporation
Index- P/E- EPS (ttm)-2.48 Insider Own0.40% Shs Outstand48.46M Perf Week4.39%
Market Cap680.38M Forward P/E- EPS next Y-1.57 Insider Trans-17.99% Shs Float46.10M Perf Month8.67%
Income-119.80M PEG- EPS next Q-0.67 Inst Own47.90% Short Float22.13% Perf Quarter10.46%
Sales21.60M P/S31.50 EPS this Y28.80% Inst Trans-0.48% Short Ratio16.26 Perf Half Y-30.29%
Book/sh-1.83 P/B- EPS next Y43.90% ROA-123.70% Target Price40.25 Perf Year24.80%
Cash/sh1.14 P/C12.33 EPS next 5Y- ROE270.20% 52W Range8.36 - 27.00 Perf YTD26.03%
Dividend- P/FCF- EPS past 5Y5.90% ROI-53.70% 52W High-48.00% Beta3.59
Dividend %- Quick Ratio2.70 Sales past 5Y60.80% Gross Margin96.20% 52W Low67.94% ATR0.69
Employees173 Current Ratio2.70 Sales Q/Q-78.80% Oper. Margin- RSI (14)57.46 Volatility4.91% 4.36%
OptionableYes Debt/Eq- EPS Q/Q-401.70% Profit Margin- Rel Volume1.44 Prev Close14.35
ShortableYes LT Debt/Eq- EarningsMar 01 BMO Payout- Avg Volume627.45K Price14.04
Recom- SMA205.24% SMA508.71% SMA200-19.93% Volume903,239 Change-2.16%
Jul-12-18Initiated Seaport Global Securities Buy $30
Mar-23-18Downgrade Wedbush Outperform → Neutral $47 → $19
Mar-05-18Downgrade Needham Buy → Hold
Nov-08-17Initiated H.C. Wainwright Buy $30
May-11-17Downgrade Cantor Fitzgerald Buy → Neutral $21 → $15
Mar-17-17Reiterated Needham Buy $24 → $22
Mar-17-17Reiterated Maxim Group Buy $19 → $22
Nov-16-16Reiterated Wedbush Outperform $56 → $47
Nov-10-16Reiterated Needham Buy $28 → $24
Aug-10-16Reiterated Maxim Group Buy $30 → $19
Jun-03-16Initiated Cantor Fitzgerald Buy $21
Mar-02-16Reiterated Needham Buy $30 → $28
Feb-29-16Reiterated Wedbush Outperform $65 → $62
Nov-11-15Reiterated Needham Buy $32 → $30
Aug-18-15Reiterated WBB Securities Strong Buy $60 → $75
Aug-10-15Initiated ROTH Capital Buy $38
Mar-18-15Reiterated Needham Buy $22 → $32
Feb-20-15Reiterated Maxim Group Buy $28 → $30
Feb-18-15Reiterated MLV & Co Buy $19 → $38
Nov-13-14Reiterated Maxim Group Buy $20 → $28
Feb-14-19 03:40PM  Why Omeros Stock Jumped Today Motley Fool +9.63%
08:30AM  Omeros Corporation Streamlines Path to Biologics License Application for OMS721 in HSCT-TMA Following Meeting with FDA Business Wire
Feb-12-19 08:30AM  Omeros Corporation Appoints Thomas F. Bumol, Ph.D., to Board of Directors Business Wire
Jan-30-19 11:14AM  Can We See Significant Insider Ownership On The Omeros Corporation (NASDAQ:OMER) Share Register? Simply Wall St.
Jan-17-19 11:11AM  Omeros Finalizes Clinical Plan For Kidney Disease Treatment, Reports Additional Positive Phase 2 Data Benzinga
08:15AM  Omeros Finalizes with FDA Clinical Plan for OMS721 Approval in IgA Nephropathy Business Wire
Jan-14-19 07:30AM  Omeros Corporation Announces Record High Quarterly Revenue Results for the Fourth Quarter 2018 Business Wire
Jan-03-19 07:35AM  Investor Expectations to Drive Momentum within L3 Technologies, The Goldman Sachs Group, Genuine Parts, Bruker, Omeros, and Aimmune Therapeutics Discovering Underlying Factors of Influence GlobeNewswire
Dec-20-18 08:30AM  Omeros Establishes Independent Academic Leadership Committee for its OMS721 Phase 3 Clinical Program in IgA Nephropathy Business Wire
Dec-11-18 07:30AM  Omeros Announces Research Collaboration with University of Cambridge Business Wire
Dec-06-18 08:30AM  Omeros Announces Clinical Strategy to Accelerate Pediatric Development of OMS721 for the Treatment of Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy (HSCT-TMA) Business Wire
Dec-03-18 08:30AM  Omeros Announces Additions to Senior Management Team Business Wire
08:14AM  Edited Transcript of OMER earnings conference call or presentation 9-Nov-18 1:30pm GMT Thomson Reuters StreetEvents
Nov-30-18 08:25AM  New Research Coverage Highlights Omeros, Apple, Bio-Rad Laboratories, Cott, Darling Ingredients, and Osisko Gold Royalties Consolidated Revenues, Company Growth, and Expectations for 2018 GlobeNewswire
Nov-29-18 11:12AM  Does Omeros Corporations (NASDAQ:OMER) CEO Salary Reflect Performance? Simply Wall St.
Nov-09-18 12:12PM  Here's Why Omeros Corporation Fell as Much as 24.5% Today Motley Fool -18.73%
07:32AM  The Daily Biotech Pulse: SITC Presentations Pick Up Pace, Sandoz' Voluntary Recall Benzinga
07:00AM  Omeros Announces Pricing of $210 Million Offering of Convertible Senior Notes Due 2023 Business Wire
06:55AM  Today's Research Reports on Trending Tickers: Omeros and Spectrum Pharmaceuticals ACCESSWIRE
Nov-08-18 05:45PM  Omeros (OMER) Reports Q3 Loss, Tops Revenue Estimates Zacks
04:41PM  Omeros: 3Q Earnings Snapshot Associated Press
04:26PM  Omeros Announces Proposed $210 Million Offering of Convertible Senior Notes Due 2023 PR Newswire
04:02PM  Omeros Corporation Reports Third Quarter 2018 Financial Results Business Wire
Nov-05-18 07:00AM  Omeros Corporation to Announce Third Quarter 2018 Financial Results on November 9, 2018 Business Wire
Nov-03-18 12:24PM  Why Omeros Corporation Fell 37.4% in October Motley Fool
Oct-23-18 08:30AM  FDA Grants Orphan Drug Designation to Omeros OMS721 for Treatment of Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy Business Wire
07:30AM  New Research: Key Drivers of Growth for Hecla Mining, Atlas Air Worldwide, Encana, Omeros, Lowe's Companies, and Oaktree Specialty Lending Factors of Influence, Major Initiatives and Sustained Production GlobeNewswire
Oct-08-18 11:15AM  Are These Beaten-Down Clinical-Stage Biotech Stocks Buys? Motley Fool +5.51%
Oct-02-18 03:32PM  Why Omeros Corporation Stock Is Bouncing Back Today Motley Fool +10.24%
08:00AM  Today's Research Reports on Trending Tickers: Omeros and Sarepta Therapeutics ACCESSWIRE
Oct-01-18 03:15PM  Omeros stock drops 45% after kidney disease trial results MarketWatch -42.81%
02:15PM  Omeros Corporation Announces Additional Positive Data for OMS721 in IgA Nephropathy Business Wire
08:45AM  Omeros Corporation Announces Reinstatement of Pass-Through Status for OMIDRIA® Business Wire
Sep-28-18 07:37AM  Best ETFs for 2018: Dont Sweat This Quarter for the SBIO ETF InvestorPlace
Sep-27-18 07:00AM  Omeros to Present at the 2018 Cantor Global Healthcare Conference Business Wire
Sep-12-18 10:18AM  Jim Cramer Shares Thoughts On Skyworks Solutions, Cypress Semiconductor, More Benzinga
Sep-11-18 06:57PM  Cramer's lightning round: Don't block the 'freight train' that is Skyworks Solutions' stock CNBC
Sep-07-18 07:00AM  Omeros to Present at the Morgan Stanley Global Healthcare Conference Business Wire
Sep-05-18 09:23AM  3 Biotech Stocks That Still Have Major Catalysts in September Motley Fool
Sep-04-18 04:11PM  Edited Transcript of OMER earnings conference call or presentation 9-Aug-18 8:30pm GMT Thomson Reuters StreetEvents
Aug-28-18 07:55AM  Detailed Research: Economic Perspectives on Allegheny Technologies, Ring Energy, Aerohive Networks, Omeros, Adtalem Global Education, and BioPharmX What Drives Growth in Today's Competitive Landscape GlobeNewswire
07:30AM  European Commission Designates OMS721 as an Orphan Medicinal Product for Treatment in Hematopoietic Stem Cell Transplantation Business Wire
Aug-10-18 08:00AM  Today's Research Reports on Trending Tickers: Omeros and Intrexon ACCESSWIRE -18.29%
07:00AM  Omeros to Present at the 2018 Wedbush PacGrow Healthcare Conference Business Wire
Aug-09-18 05:45PM  Omeros (OMER) Reports Q2 Loss, Misses Revenue Estimates Zacks
04:37PM  Omeros: 2Q Earnings Snapshot Associated Press
04:02PM  Omeros Corporation Reports Second Quarter 2018 Financial Results Business Wire
Aug-03-18 07:00AM  Omeros Corporation to Announce Second Quarter 2018 Financial Results on August 9, 2018 Business Wire
Aug-02-18 07:00AM  Omeros Hires Former Sanofi Global Development Head as Chief Medical Officer Business Wire
Jul-26-18 07:30AM  Sandoz Amends ANDA to Not Seek Approval for Generic Version of OMIDRIA Until Patents for Omeros Drug Expire Business Wire
Jul-25-18 08:30AM  Omeros OMS721 Receives European Orphan Drug Designation Positive Opinion for Treatment in Hematopoietic Stem Cell Transplantation Business Wire +5.30%
Jul-23-18 07:15AM  Omeros Corporation Initiates Sales of OMIDRIA® in Europe Business Wire +7.79%
Jul-17-18 07:00AM  Omeros Initiates Dosing in Phase 1 Clinical Trial for OMS527 Targeting Addiction Business Wire
Jul-13-18 07:40AM  Complimentary Technical Snapshots on OHR Pharma and Three More Biotech Stocks ACCESSWIRE
Jun-27-18 09:15AM  Omeros Obtains Approval to Initiate Phase 1 Clinical Trial for its OMS527 Addiction Treatment Business Wire
Jun-26-18 07:45AM  Analysis: Positioning to Benefit within The Manitowoc, Omeros, Catabasis Pharmaceuticals, Zayo Group, Covanta Holding, and Seattle Genetics Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
Jun-21-18 08:00AM  Report: Developing Opportunities within ABIOMED, Avid Technology, Unit, Omeros, Strayer Education, and NeoGenomics Future Expectations, Projections Moving into 2018 GlobeNewswire -5.29%
Jun-12-18 08:05AM  Breakfast Technical Briefing on Omeros and Three Other Additional Biotech Stocks ACCESSWIRE
May-29-18 07:10AM  Wired News Omeros Settles Lawsuit Against Lupin for Filing ANDA With FDA for Marketing Generic Version of OMIDRIA(R) ACCESSWIRE
May-24-18 07:00AM  Omeros Announces Settlement of Infringement Suit Against ANDA Filer Lupin Business Wire
May-16-18 04:40PM  Why Omeros, Party City Holdco, and Overstock.com Slumped Today Motley Fool -18.13%
May-15-18 05:51AM  Edited Transcript of OMER earnings conference call or presentation 10-May-18 8:30pm GMT Thomson Reuters StreetEvents +7.81%
May-14-18 08:00AM  Today's Research Reports on Trending Tickers: Omeros and bluebird bio ACCESSWIRE +13.98%
May-11-18 01:29PM  Here's Why Omeros Corporation Stock Is Surging Today Motley Fool +23.31%
08:00AM  Today's Research Reports on Trending Tickers: BioMarin Pharmaceutical and Omeros Corporation ACCESSWIRE
May-10-18 05:26PM  Omeros: 1Q Earnings Snapshot Associated Press
04:05PM  Omeros Corporation Reports First Quarter 2018 Financial Results Business Wire
May-07-18 10:00AM  Omeros Corporation to Announce First Quarter 2018 Financial Results on May 10, 2018 Business Wire
Apr-26-18 02:15PM  FDA Grants Breakthrough Therapy Designation to Omeros MASP-2 Inhibitor OMS721 for the Treatment of High-Risk Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy Business Wire +8.02%
Apr-19-18 07:35AM  Research Report Identifies T. Rowe Price Group, Omeros, Old Dominion Freight Line, Dillard's, BGC Partners, and Rexnord with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire
07:00AM  Additional Clinical Studies Supporting the Benefits of OMIDRIA® Presented at the American Society of Cataract and Refractive Surgery and American Society of Ophthalmic Administrators Annual Meeting Business Wire
Apr-13-18 09:10AM  Omeros Corporation Announces Upcoming Presentations of New Data on OMIDRIA® at the American Society of Cataract and Refractive Surgery Meeting Business Wire -5.59%
Apr-12-18 09:10AM  OMIDRIA® Added to Veterans Health Administration National Formulary Business Wire
Apr-11-18 09:15AM  Omeros Announces Amendment of Credit Facility Business Wire +9.64%
Apr-04-18 09:51AM  What Should Investors Know About Omeros Corporations (NASDAQ:OMER) Growth? Simply Wall St. +11.03%
Mar-26-18 12:33PM  Omeros, Mattel, And 3 Other Stocks In Clear Trending Patterns This Week Benzinga -12.88%
Mar-23-18 06:56AM  ICYMI: GameStop, Omeros, Congress Impacts Biotechs Benzinga -10.54%
Mar-22-18 05:28PM  New Budget Deals Big Pharma a Blow on Medicare Part D, but Omeros Scores TheStreet.com +35.31%
04:31PM  Why Lands' End, Omeros, and MGP Ingredients Jumped Today Motley Fool
03:42PM  Omeros Elevated By Medicare Reimbursement And OMS721 Progress, Says Maxim Benzinga
12:09PM  Here's Why Omeros Corporation Is Bouncing Back Today Motley Fool
11:46AM  Biotech Winners And Losers From Congress' Latest Funding Bill Benzinga
11:34AM  Omeros shares surge 45% on spending bill that benefits its drug MarketWatch
09:18AM  Omeros Corporation (NASDAQ:OMER): Is Breakeven Near? Simply Wall St.
08:39AM  Benzinga Pro's 5 Stocks To Watch Today Benzinga
Mar-05-18 08:17AM  Is Omeros Corporation a Buy on the Dip? Motley Fool
Mar-02-18 08:20AM  Todays Research Reports on Trending Tickers: Omeros and Opko Health ACCESSWIRE
08:06AM  Edited Transcript of OMER earnings conference call or presentation 1-Mar-18 9:30pm GMT Thomson Reuters StreetEvents
Mar-01-18 04:53PM  Omeros reports 4Q loss Associated Press
04:02PM  Omeros Corporation Reports Fourth Quarter and Year-End 2017 Financial Results Business Wire
12:30PM  Omeros Corporation to Host Earnings Call ACCESSWIRE
Feb-26-18 09:30AM  Omeros Corporation to Announce Fourth Quarter and Year-End 2017 Financial Results on March 1, 2018 Business Wire +10.60%
Feb-15-18 07:42AM  Omeros Reports Significant Improvement in Overall Survival Data in OMS721-Treated Patients with Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy Business Wire
Feb-14-18 04:33PM  Why Biogen, Groupon, and Omeros Slumped Today Motley Fool -17.58%
03:54PM  The Report that Sent Omeros Corporation (OMER) Shares Tumbling SmarterAnalyst
01:27PM  Here's Why Omeros Corporation Is Getting Beaten Down on Wednesday Motley Fool
09:00AM  Short Seller Who Predicted Plunge in Flotek Has a New Target Bloomberg
Feb-09-18 07:40AM  Report: Exploring Fundamental Drivers Behind Bank of Hawaii, Omeros, OneMain, Veritex, Versum Materials, and SiteOne Landscape Supply New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire
Jan-22-18 07:00AM  European Medicines Agency Issues Orphan Drug Designation Positive Opinion for Omeros OMS721 in the Treatment of IgA Nephropathy Business Wire
Jan-11-18 03:00AM  Omeros Scores Relative Strength Rating Upgrade; Hits Key Threshold Investor's Business Daily
Omeros Corporation, a biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company markets OMIDRIA for use in cataract surgery or intraocular lens replacement in the United States. Its clinical programs include OMS721 that is in Phase III clinical trial for treating immunoglobulin A (IgA) nephropathy, hematopoietic stem cell transplant-associated thrombotic microangiopathy (HCT-TMA), and atypical hemolytic uremic syndrome (aHUS); and in Phase II clinical trial to treat IgA nephropathy, membranous nephropathy, lupus nephritis, and complement component glomerulopathy. The company's clinical programs also consists of OMS824, which is in Phase II clinical trial for treating Huntington's diseases and schizophrenia; and OMS405 that is in Phase II clinical trial to treat opioids, nicotine, and alcohol addiction. Its preclinical programs comprise OMS527 for the treatment of addiction and compulsive disorders, as well as for movement disorders; and OMS906 to treat paroxysmal nocturnal hemoglobinuria and other alternative pathway disorders. The company's preclinical programs also include MASP-2-small-molecule inhibitors used for the treatment of aHUS, IgAN, HCT-TMA, and age-related macular degeneration; MASP-3-small-molecule inhibitors used for the treatment of PNH and other alternative pathway disorders; G protein-coupled receptor (GPCR) platform, including GPR174 and other Class A orphan GPCRS for treating CNS, metabolic, CV, oncologic, musculoskeletal, and other disorders; and antibody platform for metabolic, CV, oncologic, musculoskeletal and other disorders. Omeros Corporation was incorporated in 1994 and is based in Seattle, Washington.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Kelbon Marcia S.VP Patent and General CounselAug 31Option Exercise5.1015,52979,269200,645Aug 31 09:32 PM
Kelbon Marcia S.VP Patent and General CounselAug 31Sale25.757,529193,846192,645Aug 31 09:32 PM
Kelbon Marcia S.VP Patent and General CounselAug 30Option Exercise4.1035,000143,500227,645Aug 31 09:32 PM
Kelbon Marcia S.VP Patent and General CounselAug 30Sale24.4535,000855,750192,645Aug 31 09:32 PM
Kelbon Marcia S.VP Patent and General CounselJul 27Option Exercise4.105,72323,464198,368Jul 30 07:00 PM
Kelbon Marcia S.VP Patent and General CounselJul 27Sale21.735,723124,357192,645Jul 30 07:00 PM
Kelbon Marcia S.VP Patent and General CounselJul 26Option Exercise4.4643,000191,900219,645Jul 30 07:00 PM
Kelbon Marcia S.VP Patent and General CounselJul 26Sale21.5335,000753,687184,645Jul 30 07:00 PM
Kelbon Marcia S.VP Patent and General CounselJul 12Option Exercise4.104,27717,536188,922Jul 13 08:00 PM
Kelbon Marcia S.VP Patent and General CounselJul 12Sale21.484,27791,886184,645Jul 13 08:00 PM
JACOBSEN MICHAEL AVP Finance and CAOMay 15Option Exercise9.3717,812166,89821,312May 16 06:00 PM
JACOBSEN MICHAEL AVP Finance and CAOMay 15Sale24.9512,812319,6598,500May 16 06:00 PM
JACOBSEN MICHAEL AVP Finance and CAOMay 14Option Exercise9.3710,980102,88319,480May 16 06:00 PM
JACOBSEN MICHAEL AVP Finance and CAOMay 14Sale22.4510,980246,5018,500May 16 06:00 PM